Back to search

Article

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner

2025-12-05

Abstract excerpt

Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) has been the standard care for muscle-invasive bladder cancer (MIBC) for two decades. One third of NAC-treated patients achieve pathologic complete response (pT0N0), a proxy for improved survival after RC. Predicting response already at transurethral resection of bladder tumor (TUR-BT) would enable selective use of NAC, minimizing u...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ea1246b8-feac-539a-8f2a-dc9f921ed1f7
DOI
10.64898/2025.12.04.25341613
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent mannerDOI 10.64898/2025.12.04.25341613
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Semantic proximity
Tumor Immune Infiltration as a Predictor of Response to Neoadjuvant Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: An Integrative TCGA AnalysisSemantic proximity
Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevanceSemantic proximity
Identification of an immunotherapy-responsive molecular subtype of bladder cancer.Semantic proximity
Risk Classification of Bladder Cancer by Gene Expression and Molecular SubtypeSemantic proximity
Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.Semantic proximity
Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non–Muscle-Invasive Bladder CancerSemantic proximity
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.Semantic proximity
Subtype-specific benefit of adjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer with histologic variants: a four-endpoint, subtype-stratified analysisSemantic proximity
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.Semantic proximity
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity
Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene AssessmentSemantic proximity
Select a neighboring publication to make it the new centre.